- Trial phase
- Preclinical
- Time to market
- Years away; the drug is still in preclinical development with no IND filed as of November 2026. Even after IND clearance, Phase 1, 2, and 3 trials typically take 5-8 years before potential approval.
- Why 3/10
- STRO-227 is a preclinical-stage PTK7-targeting dual-payload ADC with no IND filed as of the latest Q3 2026 report (November 12, 2026). The company guided IND submission in 2026 in its August 2026 earnings release, but the Q3 2026 update did not mention STRO-227 specifically, suggesting timelines may have shifted. No hard dated catalyst exists in the next ~12 months.
STRO-227 is an early-stage, preclinical asset with no human data and no confirmed IND timeline. Investors should watch for an IND filing announcement or a pipeline update from Sutro that clarifies whether STRO-227 remains on track. The stock's primary near-term catalyst is the STRO-004 Phase 1 data update expected in the first half of 2027, not STRO-227.
Price Chart
Executive Summary
STRO-227 is a preclinical, PTK7-targeting dual-payload ADC being developed by Sutro Biopharma (STRO). It showed dose-dependent antitumor activity in preclinical models presented at AACR in April 2026. The company guided an IND submission in 2026, but as of the November 12, 2026 Q3 earnings report, no IND has been filed and STRO-227 was not specifically mentioned. It is one of several next-generation pipeline candidates behind the lead program STRO-004 (Phase 1, tissue-factor targeting ADC). With no human data, no filed IND, and no hard dated catalyst, STRO-227 is a distant pipeline option rather than a near-term value driver for STRO shares.
How It Works
STRO-227 is an antibody-drug conjugate (ADC), a type of cancer drug that works like a guided missile. It targets a protein called PTK7 found on the surface of certain cancer cells. The "dual-payload" design means it carries two different chemotherapy drugs, which it delivers directly to tumor cells to kill them while sparing healthy tissue. Sutro's platform allows precise, site-specific attachment of the drugs to the antibody.
Trial Status
STRO-227 is a preclinical-stage, PTK7-targeting dual-payload antibody-drug conjugate (ADC). It was included in Sutro's AACR 2026 poster presentation (April 2026), where it showed "meaningful, dose-dependent antitumor activity across solid tumor models" alongside STRO-006. In the August 2026 Q2 earnings release, Sutro guided that STRO-227's IND submission was expected in 2026. However, the most recent Q3 2026 earnings release (November 12, 2026) did not specifically mention STRO-227, and no IND filing has appeared in SEC filings or press releases through November 13, 2026.
The Two-Sided Case
Upcoming Catalysts
- IND filing announcement for STRO-227 (timeline uncertain; previously guided for 2026 but not yet filed as of November 2026)
- Next pipeline update from Sutro, potentially at a scientific conference or in the Q4 2026 earnings release
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sutro Biopharma, Inc. PRESS-RELEASE STRO ·Originating report